- Archives
-
-
-
-
-
-
-
-
-
-
-
Gil Y. Roth
Gil Y. Roth
Catching up with our first issue’s contributors
Gil Y. Roth
Developing a process for working with providers
Nelson M. Lugo
No option but to outsource?
Enrico T. Polastro, Ph.D., and Sonia Tulcinsky
New concepts in colonic drug targeting
Dr. Stephen Brown
Harmonizing extant FDA regulations and international cGMPs
Debbie Thomas
Learning lessons from other industries
Chris Driscoll
Anthony Grilli
Creating opportunities for lower costs and faster time-to-market
Peter Soelkner
Measuring risk in sourcing
Helena Champion
An effective approach to realizing a sourcing solution
Chris Albani, Greg Meline, and Bryan Katz
Analyzing the past, anticipating the future
Susan Toth
Gil Roth
Opportunities in uncertain times
Kristin Brooks
Strategies for getting to Phase I quicker and saving API
Paul Skultety, Ph.D.
A versatile ingredient works in excipient applications
Gerald K. Schalau II and Katherine L. Ulman
Aseptic blow/fill/seal vs. traditional aseptic processing
Chuck Reed
Innovation, trends and challenges
Kristin Brooks
Recent changes in security affect pharma facilities
Evan Wolff, Maida Oringher Lerner, and Matthew Melewski
Can e-integration speed drug development?
Robert Barr
Gil Roth
Trends and differences in the U.S. & Western Europe
Eric S. Langer
CMOs can design for disposable components
Tony Garbarino and Dave Odegaard
Optimism remains high among bio-contract manufacturers
William Downey
Cold chain management is essential in biopharma development
Jeff Clark
New models, new partnerships
Marcelo Morales
More features and columns in our print edition
Gil Roth
Tips and tactics for optimizing your CMO partnership
Carlos R. Fernandez and Douglas A. Jonas
Strategies for assessment of leachables in parenteral drugs
Diane M. Paskiet
Avoid the pitfalls and realize powerful benefits
Fred Greulich
Where’s the bio/pharma money and how is it being spent?
Tom Spurgeon
More features and columns in our print edition
Gil Roth
Do we see a new paradigm in pharmaceutical manufacturing?
Dr. Enrico T. Polastro
Success in Partnerships
Pedram Alaedini and Howard Kim
New delivery forms create new challenges
Mike Bly, Ph.D.
Get out of the silos
Brian Karlak
Stronger, Smarter, and not Quite so Big
Neil Canavan
Reviewing 2008’s mergers, acquisitions and buyouts
Michael A. Martorelli
How will the new regulations affect your EU imports?
Carole Garcia
How to combat cost structures in R&D
Neil MacAllister, Richard Evans, and Katherine Wallace
10 things pharma executives need to know about improvement
Ronald D. Snee
|
Magazine
